Melanoma & Skin Cancer

Ameluz-PDT generated statistically significant target lesion clearance outcomes vs placebo-PDT in superficial basal cell carcinoma.

This roundup includes exclusive insights from 23 clinicians and key data on the top abstracts coming out of the 2024 ESMO Annual Meeting.

Treatment options after progression on anti–PD-1 and BRAF/MEK inhibitors have been limited but TIL therapy has expanded metastatic melanoma treatment.

IMA203, a TCR-T agent targeting PRAME, was safe and effective in patients with heavily pretreated melanoma.

Thach-Giao Truong, MD, discusses the ImmunoCobiVem trial investigating the switch from targeted therapy to immunotherapy in advanced BRAF V600+ melanoma.

Alexander C. Van Akkooi, MD, PhD, FRACS, discusses the prognostic value of minimal sentinel node tumor burden in melanoma.

Meredith McKean, MD, discusses the efficacy of fianlimab given in combination with cemiplimab for patients with advanced melanoma.

Richard Vile, PhD, explains how CAR-T cell therapy works, including the benefits, risks and realities of treatment.

Fianlimab plus cemiplimab demonstrated persistent and significant clinical activity in patients with advanced melanoma.

Early switch therapy to atezolizumab after run-in with vemurafenib plus cobimetinib led to improved 4- and 5-month OS rates in BRAF V600–positive melanoma.

RP1 plus nivolumab offers durable responses and a favorable safety profile for patients with melanoma after progression on anti–PD-1 therapy.

Pembrolizumab continued to demonstrate improved survival vs ipilimumab in unresectable stage III or IV melanoma.

The CheckMate 067 trial of patients with advanced melanoma is the longest follow-up of a checkpoint inhibitor in any tumor type.

Findings from the phase 2 RELATIVITY-104 study demonstrates a clinical benefit with the addition of relatlimab to nivolumab and chemotherapy.

The FDA has approved subcutaneous atezolizumab for use in all indications as the intravenous formulation.

First-line bel-sar displayed tumor control and preserved visual acuity in early-stage choroidal melanoma.

Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress.

About 8 to 10 million Americans over 40 have excess white blood cells, which may increase their risk of melanoma.

The FDA has granted fast track designation to the MCR1-targeted theranostic ligand VMT01 for unresectable or metastatic melanoma.

The FDA has granted fast track designation to IBI363 for unresectable advanced or metastatic melanoma after progression on at least 1 line of therapy.

The phase 3 IOB-013/KN-D18 trial of IO102-IO103 plus pembrolizumab in advanced melanoma will continue without modifications.

Here is your snapshot of all therapeutic options that the FDA approved in August 2024 and their clinical implications.

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2024.

The phase 3 KEYNOTE-867 and KEYNOTE-630 trials evaluating pembrolizumab in NSCLC and CSCC, respectively, have been discontinued by Merck.

Ankit Mangla, MD, expands on key survival data from the phase 2/3 RELATIVITY-047 trial in previously untreated, unresectable, or metastatic melanoma.